<SUBMISSION>
<ACCESSION-NUMBER>0000950148-02-001765
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20020725
<ITEMS>5
<ITEMS>7
<FILING-DATE>20020730
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>02713679
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v83206e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>ADVANCED BIOTHERAPY, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="center"><FONT size="2"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</B></FONT>

<P align="center"><FONT size="2"><B>FORM 8-K</B></FONT>

<P align="center"><FONT size="2"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="28%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="20%">&nbsp;</TD>
     <TD width="51%">&nbsp;</TD>

</TR>

<TR valign="bottom">
        <TD valign="top" nowrap><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">Date of Report (Date of earliest reported)</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
July&nbsp;25, 2002</FONT></DIV></TD>
</TR>
<TR>
        <TD valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
<HR size="1" noshade></FONT></DIV></TD>
</TR>
</TABLE>
<P align="center"><FONT size="2">Advanced Biotherapy, Inc.</FONT>



<DIV align="center"><FONT size="2"><FONT size="2">(Exact name of registrant as specified in its chapter)</FONT></FONT></DIV>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="34%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="28%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="28%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">Delaware</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
0-26323
</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">95-0402415</FONT></DIV></TD>
</TR>
<TR>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><HR size="1" noshade></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
<HR size="1" noshade>
</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><HR size="1" noshade></DIV></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">(State or other jurisdiction<BR>
of incorporation)</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
(Commission<BR>
File Number)
</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">(IRS Employer<BR>
Identification No.)</FONT></DIV></TD>
</TR>
</TABLE>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="30%">&nbsp;</TD>
        <TD width="10%">&nbsp;</TD>
     <TD width="8%">&nbsp;</TD>
        <TD width="44%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="7%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD valign="top" nowrap><FONT size="2">6355 Topanga Canyon Boulevard, Suite&nbsp;510</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
91367</FONT></TD>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR>
        <TD valign="top"></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="right" valign="top"><FONT size="2">
<HR size="1" noshade></FONT></TD>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR>
        <TD valign="top"><FONT size="2">Woodland Hills, California
</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap valign="top"><FONT size="2">(Zip Code)</FONT></TD>
</TR>
<TR><TD><HR size="1" noshade></TD></TR>
<TR><TD><FONT size="2">(Address of principal executive offices)</FONT></TD></TR>

</TABLE>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="35%">&nbsp;</TD>
        <TD width="10%">&nbsp;</TD>
        <TD width="55%">&nbsp;</TD>
</TR>
<TR><TD nowrap><FONT size="2">Registrant&#146;s telephone number, including area code</FONT></TD>
<TD  align="center" nowrap><FONT size="2">(818)&nbsp;883-6716</FONT></TD>
<TR><TD>&nbsp;</TD>
<TD><FONT size="2">
<HR size="1" noshade></FONT></TD></TR>

</TR>

</TABLE>
<!-- PAGEBREAK -->
<P><HR noshade><P>


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;5. OTHER EVENTS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signatures</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="v83206exv99w1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link2 "Item&nbsp;5. OTHER EVENTS." -->
<DIV align="left"><A NAME="000"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;5. OTHER EVENTS.</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant published a press release on July&nbsp;25, 2002, which reported
that Dr.&nbsp;Hillel Panitch, Professor of Neurology and Director of the Multiple
Sclerosis Center at Fletcher Allen Health Center, University of Vermont College
of Medicine, has joined Advanced Biotherapy, Inc.&#146;s Multiple Sclerosis
Scientific Advisory Board.
</FONT>
<!-- link2 "Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS" -->
<DIV align="left"><A NAME="001"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</FONT>

<P align="left"><FONT size="2">(c)&nbsp;Exhibits.</FONT>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="27%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="68%">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">Designation<br>
99.1</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; "><FONT size="2">
Description of Exhibit<BR>
Press Release, dated July&nbsp;25, 2002</FONT></DIV></TD>
</TR>
</TABLE>

<P align="center"><FONT size="2">Signatures</FONT>
<P align="LEFT"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</FONT>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="002"></A></DIV>
<TR valign="bottom">
        <TD width="31%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="3%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="30%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD colspan="4" align="left" valign="top"><DIV style="margin-left:10px;"><FONT size="2">ADVANCED BIOTHERAPY, INC.<BR>
(Registrant)</FONT></DIV></TD>
        <TD valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>

</TR>
<TR><TD>&nbsp;</TD></TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
        <TD valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">Date:July&nbsp;25, 2002</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="right" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
By:
</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>

<TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">/s/ Edmond Buccellato</FONT></DIV></TD>
</TR>
<TR>
        <TD valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><HR size="1" noshade></DIV></TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>

<TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">Edmond Buccellato, President and CEO</FONT></DIV></TD>
</TR>
</TABLE>

<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="003"></A></DIV>

<P align="center"><FONT size="2">INDEX TO EXHIBITS</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="55%">
<TR valign="bottom">
        <TD width="17%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="78%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">Exhibit</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
Description</FONT></DIV></TD>
</TR>
<TR>
        <TD valign="top"><DIV style="margin-left:10px; text-indent:-10px"><HR size="1" noshade></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
<HR size="1" noshade></FONT></DIV></TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">99.1</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
Text of Press Release, dated July&nbsp;25, 2002</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">
</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v83206exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>ADVANCED BIOTHERAPY, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P align="left"><FONT size="2">EXHIBIT 99.1</FONT>

<P align="left"><FONT size="2"><B>Dr.&nbsp;Hillel Panitch Joins Advanced Biotherapy&#146;s Multiple Sclerosis Medical
Advisory Board</B></FONT>

<P><FONT size="2">WOODLAND HILLS, Calif.&#151; (BW HealthWire)&#151; July&nbsp;25, 2002&#151; Advanced Biotherapy,
Inc. (OTCBB: ADVB &#151; News) announced today that Dr.&nbsp;Hillel Panitch, Professor of
Neurology and Director of the Multiple Sclerosis Center at Fletcher Allen
Health Care, University of Vermont College of Medicine, has joined the
Company&#146;s Multiple Sclerosis Scientific Advisory Board.
</FONT>
<P><FONT size="2">Commenting on the announcement, ADVB&#146;s President and CEO, Edmond Buccellato,
stated, &#147;We are pleased to have someone with the reputation and experience of
Dr.&nbsp;Panitch as an advisor to our company. Dr.&nbsp;Panitch is a world-renowned
neurologist, whose work in multiple sclerosis (MS)&nbsp;is well recognized by the
scientific community. In his 1987 article entitled, &#145;Treatment of MS With gamma
Interferon: Exacerbations Associated with Activation of the Immune System&#146;
(Neurology 31:1097-1103), Dr.&nbsp;Panitch was the first to report that
administration of gamma interferon to patients with MS exacerbates their
disease. This conclusion is consistent with our company&#146;s strategy to treat MS
and other autoimmune diseases by controlling the immune system&#146;s release of
gamma interferon.&#148;
</FONT>
<P><FONT size="2">Dr.&nbsp;Panitch was graduated from the NYU School of Medicine and completed his
residency in Neurology at the University of California San Francisco, followed
by post-doctoral fellowships in Neurovirology and Neuroimmunology at Johns
Hopkins University and the National Institutes of Health, respectively. Widely
published, he spent several years conducting basic research on experimental
autoimmune encephalomyelitis (EAE), the animal model of MS, prior to pursuing
clinical trials in experimental immunotherapy, an area of expertise that he has
pursued for over 20&nbsp;years. Dr.&nbsp;Panitch&#146;s research has been supported by the
National Multiple Sclerosis Society, the Department of Veterans Affairs and the
pharmaceutical industry. He has also served on committees of the Multiple
Sclerosis Society and is a frequent speaker and consultant on a variety of
topics related to experimental therapies and the clinical management of MS.
</FONT>
<P><FONT size="2">In addition to being a practicing physician, Dr.&nbsp;Panitch has played a key role
as a research scientist and principal investigator in clinical trials of
interferon beta-1a and interferon beta-1b for the treatment of MS. He is
currently developing a comprehensive MS center that will serve patients in
Northern New England and Upstate New York. Several clinical trials of potential
therapies for MS are currently underway at the center.
</FONT>
<P><FONT size="2">In a quote regarding Advanced Biotherapy&#146;s approach for the treatment of MS,
Dr.&nbsp;Panitch stated, &#147;Because gamma interferon has been shown to play a pivotal
role in the pathogenesis of MS, the strategy of targeting and down regulating
it directly is very promising as a potential treatment for this disease and
should be pursued as part of the company&#146;s plans for future clinical trials.
I&#146;m pleased to be associated with the company as an advisor.&#148;
</FONT>
<P><FONT size="2">Advanced Biotherapy Inc., headquartered in Woodland Hills, California, is
engaged in developing and patenting new biological treatments for a range of
autoimmune diseases based on an anti-cytokine platform technology. The United
States Patent and Trademark Office (USPTO)&nbsp;issued a patent to ADVB for the
exclusive use of antibodies to gamma interferon &#151; including humanized and
fully human, as well as other antibody types &#151; to treat MS, Rheumatoid
Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis (a form of
psoriasis) and Ankylosing Spondylitis. Patent applications are pending for the
exclusive use of gamma interferon antibodies in any form to treat Corneal
Transplant Rejection, Psoriasis, Crohn&#146;s Disease, Alopecia Areata and Vitiligo.
</FONT>
<P><FONT size="2">Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties
that could cause actual results to differ materially from the anticipated
results or other expectations expressed in our forward-looking statements. The
risks and uncertainties which may affect the development, operations and
results of our business include, but are not limited to the following: risks
associated with clinical trials, the uncertainties of research and product
development programs, the uncertainties of the regulatory approval process, the
risks of competitive products, the risks of our current capital resources, the
uncertainties as to the availability of future capital and our future capital
requirements, and the risks associated with the extent and breadth of the
Company&#146;s patent portfolio. The Company&#146;s patents, issued and pending, involve
risks
</FONT>
<P align="center"><FONT size="2">
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P><FONT size="2">and uncertainties, including but not limited to the risks that third parties
may be successful in challenging such patents; or that granted claims may be
held invalid or interpreted differently by a court of law; or that new
technologies will be developed that are superior in treating the diseases
targeted by Advanced Biotherapy, Inc. Readers are cautioned not to place
reliance on these forward-looking statements, which speak only as of the date
the statements were made. See the Company&#146;s public filings with the Securities
and Exchange Commission for further information about risks and uncertainties
that may affect the Company and the results or expectations expressed in our
forward-looking statements, including the section captioned &#147;Factors That May
Affect The Company&#148; contained in the Company&#146;s Annual Report on Form&nbsp;10-KSB for
the fiscal year ended December&nbsp;31, 2001.
</FONT>
<P><FONT size="2"><I>Contact:</I>
</FONT>
<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
        <TD width="5%"><FONT size="2">&nbsp;</FONT></TD>
        <TD width="95%"><FONT size="2">Advanced Biotherapy, Inc.<BR>
Edmond Buccellato, 818/883-6716, Ext. 2<BR>
E-mail: ed@advancedbiotherapy.com<BR>
Website: www.advancedbiotherapy.com</FONT></TD>
</TR>
</TABLE>

<P align="center"><FONT size="2"></FONT>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
